Psoriasis: all 1,928 studies

Page 5 of 20. Open to participants first (234), then studies with results posted, then the rest; newest registration first within each.

• Initial Dosing of BI 655130 in Palmoplantar Pustulosis PatientsCompletedNCT03135548Phase 2Results posted
• Safety and Efficacy of Secukinumab in Mild PsoriasisCompletedNCT03131570Phase 2Results posted
• A Study of the Efficacy and Safety of Apremilast (CC-10004) in Subjects With Moderate to Severe Plaque Psoriasis of the ScalpCompletedNCT03123471Phase 3Results posted
• A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD)CompletedNCT03104400Phase 3Results posted
• A Study Comparing Upadacitinib (ABT-494) to Placebo in Participants With Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Biologic Disease Modifying Anti-Rheumatic DrugCompletedNCT03104374Phase 3Results posted
• A Study to Evaluate the Comparative Efficacy of CNTO 1959 (Guselkumab) and Secukinumab for the Treatment of Moderate to Severe Plaque-type PsoriasisCompletedNCT03090100Phase 3Results posted
• Vascular Inflammation in Psoriasis - ApremilastCompletedNCT03082729Phase 4Results posted
• A Study of Ixekizumab in Chinese Participants With Psoriasis VulgarisCompletedNCT03073213Phase 1Results posted
• Study of Ixekizumab (LY2439821) in Children 6 to Less Than 18 Years With Moderate-to-Severe Plaque PsoriasisCompletedNCT03073200Phase 3Results posted
• Study of Efficacy and Safety of Secukinumab in Subjects With Moderate to Severe Chronic Plaque-type PsoriasisCompletedNCT03066609Phase 3Results posted
• Study to Explore the Effect of Secukinumab, Compared to Placebo, on Fat Tissue and Skin in Plaque Psoriasis PatientsCompletedNCT03055494Phase 4Results posted
• A Study to Test the Efficacy and Safety of Certolizumab Pegol in Japanese Subjects With Moderate to Severe Chronic PsoriasisCompletedNCT03051217Phase 2/3Results posted
• Evaluating Treatment Resistant Dermatitis TaroIIRCompletedNCT03050294Phase 4Results posted
• A Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe Plaque Type Psoriasis ( LIMMITLESS )CompletedNCT03047395Phase 3Results posted
• A Study to Evaluate the Pharmacokinetics (PK), Pharmacodynamics (PD), and Safety of Bimekizumab in Patients With Chronic Plaque PsoriasisCompletedNCT03025542Phase 2Results posted
• Safety and Efficacy of CD10367 in Psoriasis VulgarisCompletedNCT03025282Phase 2Results posted
• A Study Evaluating the Efficacy and Tolerability of Oral Apremilast for the Treatment of Nail PsoriasisCompletedNCT03022617Phase 4Results posted
• A Study to Assess Efficacy and Safety of Two Different Dose Regimens of Risankizumab Administered Subcutaneously in Japanese Subjects With Generalized Pustular Psoriasis or Erythrodermic PsoriasisCompletedNCT03022045Phase 3Results posted
• Study of the Efficacy of Early Intervention With Secukinumab 300 mg s.c. Compared to Narrow-band UVB in Patients With New-onset Moderate to Severe Plaque PsoriasisCompletedNCT03020199Phase 4Results posted
• A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Patients With Chronic Plaque PsoriasisCompletedNCT03010527Phase 2Results posted
• A Study of GSK2981278 Ointment in Subjects With Plaque PsoriasisCompletedNCT03004846Phase 1/2Results posted
• A Trial of a Botanical Drug (EISO) for Treatment of Mild-to-Moderate Plaque PsoriasisCompletedNCT03000608Phase 2Results posted
• Use of Apremilast in Patients Who Are Dissatisfied With Stable Maintenance Topical TherapyCompletedNCT03000309Phase 4Results posted
• BI 655066 (Risankizumab) Compared to Placebo in Japanese Patients With Moderate to Severe Chronic Plaque PsoriasisCompletedNCT03000075Phase 2Results posted
• A Study of Ixekizumab in Participants With Plaque PsoriasisCompletedNCT02993471Phase 1Results posted
• Topical Scalp Psoriasis Study Evaluating Topicort Topical SprayCompletedNCT02985736Phase 4Results posted
• Topical Psoriasis Study for Patients Receiving Biologic TherapyCompletedNCT02983981Phase 4Results posted
• Spesolimab (BI 655130) Single Dose in Generalized Pustular PsoriasisCompletedNCT02978690Phase 1Results posted
• Study To Evaluate Safety And Efficacy Of PF-06700841 In Subjects With Moderate To Severe Plaque PsoriasisCompletedNCT02969018Phase 2Results posted
• A Study to Compare the Efficacy of Guselkumab to Fumaric Acid Esters for the Treatment of Participants With Moderate to Severe Plaque PsoriasisCompletedNCT02951533Phase 3Results posted
• Phase III Clinical Study in Patients With Mild to Severe Scalp PsoriasisCompletedNCT02933866Phase 3Results posted
• Safety Study to Assess the Potential for Adrenal Suppression Following Maximal Use Treatment With DSXSCompletedNCT02933528Phase 2Results posted
• Safety Study in Patients With Scalp Psoriasis Suppression Following Maximal Use Treatment With Topical ProductCompletedNCT02933502Phase 2Results posted
• An Open Label, Safety Study to Assess the Potential for Adrenal SuppressionCompletedNCT02932878Phase 2Results posted
• Study to Evaluate Efficacy and Safety of the Topical Product in Patients With Mild to Severe Scalp PsoriasisCompletedNCT02932462Phase 3Results posted
• Study to Evaluate Effectiveness and Safety in Subjects With Moderate to Severe PsoriasisCompletedNCT02931838Phase 2Results posted
• Study to Evaluate Safety and Efficacy of Oral MP1032 in Psoriasis PatientsCompletedNCT02908347Phase 2Results posted
• Efficacy and Safety Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type PsoriasisCompletedNCT02905331Phase 3Results posted
• Study to Evaluate Safety and Efficacy of Different Doses of Bimekizumab in Patients With Chronic Plaque PsoriasisCompletedNCT02905006Phase 2Results posted
• A Study of Mirikizumab (LY3074828) in Participants With Moderate to Severe Plaque PsoriasisCompletedNCT02899988Phase 2Results posted
• LEO 90100 Twice Weekly Maintenance Regimen for Psoriasis VulgarisCompletedNCT02899962Phase 3Results posted
• A Study Comparing Tazarotene Cream 0.05% to TAZORAC® (Tazarotene) Cream 0.05% and Both to a Placebo Control in the Treatment of Plaque PsoriasisCompletedNCT02886702Phase 3Results posted
• An Efficacy and Safety Study of LYC-30937-EC in Subjects With Moderate Chronic Plaque-type PsoriasisCompletedNCT02872285Phase 2Results posted
• Adherence in Topical Treatment of PsoriasisCompletedNCT02858713Phase 4Results posted
• A Phase 2, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Belumosudil in Subjects With Moderate/Severe Chronic Plaque PsoriasisCompletedNCT02852967Phase 2Results posted
• Efficacy, Safety and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque PsoriasisCompletedNCT02850965Phase 3Results posted
• Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque PsoriasisCompletedNCT02826603Phase 3Results posted
• Safety and Efficacy of IDP-122 Lotion When Applied Topically to Subjects With Moderate to Severe Plaque PsoriasisCompletedNCT02785185Phase 2Results posted
• Safety and Efficacy of IDP-118 Lotion to Ultravate® in the Treatment of Plaque PsoriasisCompletedNCT02785172Phase 2Results posted
• Safety and Efficacy of IDP-118 Lotion in the Treatment of Plaque PsoriasisCompletedNCT02785159Phase 2Results posted
• Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Repeat Doses of GSK2982772 in Subjects With PsoriasisCompletedNCT02776033Phase 2Results posted
• International Clinical Trial to Evaluate Efficacy and Safety of Multiple Subcutaneous Injections of BCD-085 in Various Doses in Patients With Moderate to Severe Plaque PsoriasisCompletedNCT02762994Phase 2Results posted
• A Study to Evaluate Clear Skin Effect on Quality of Life in Patients With Plaque Psoriasis.CompletedNCT02752776Phase 4Results posted
• Post-marketing Observational Study to Evaluate the Incremental Impact of AbbVie's Patient Support Program on Patient Reported Outcomes and Health Resource Utilization in Inflammatory Arthritis, Psoriasis and Inflammatory Bowel Diseases in Hungary (VALUE)CompletedNCT02750800Results posted
• Patient Satisfaction Following Twice Daily Dosing With DFD-01 in Subjects With Moderate Plaque PsoriasisCompletedNCT02749799Phase 4Results posted
• Study of Secukinumab With 2 mL Pre-filled SyringesCompletedNCT02748863Phase 3Results posted
• A Comparison of 122-0551 Foam Versus Vehicle Foam in Subjects With Plaque Psoriasis (Study 310)CompletedNCT02742441Phase 3Results posted
• Efficacy and Safety of Blue Light (453 nm) Treatment for Mild Psoriasis Vulgaris Over Three Months Compared to Vitamin D.CompletedNCT02735187Not applicableResults posted
• A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Genital PsoriasisCompletedNCT02718898Phase 3Results posted
• Effectiveness of Artificial Balneotherapy, Phototherapy and Artificial Balneophototherapy in the Treatment of PsoriasisCompletedNCT02713711Not applicableResults posted
• An Efficacy, Safety, and Pharmacokinetics Study of Subcutaneously Administered Ustekinumab in the Treatment of Moderate to Severe Chronic Plaque Psoriasis in Pediatric Participants Greater Than or Equal to 6 to Less Than 12 Years of AgeCompletedNCT02698475Phase 3Results posted
• BI 655066/ABBV-066 (Risankizumab) Compared to Active Comparator (Adalimumab) in Patients With Moderate to Severe Chronic Plaque PsoriasisCompletedNCT02694523Phase 3Results posted
• Study to Evaluate the Effect of Secukinumab Compared to Placebo on Aortic Vascular Inflammation in Subjects With Moderate to Severe Plaque PsoriasisCompletedNCT02690701Phase 4Results posted
• BI 655066 (Risankizumab) Compared to Placebo and Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque PsoriasisCompletedNCT02684370Phase 3Results posted
• BI 655066 Versus Placebo & Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque PsoriasisCompletedNCT02684357Phase 3Results posted
• BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatmentCompletedNCT02672852Phase 3Results posted
• LEO 80185 Gel (Calcipotriol Hydrate Plus Betamethasone Dipropionate) in Japanese Subjects With PsoriasisCompletedNCT02668692Phase 3Results posted
• MSB11022 in Moderate to Severe Chronic Plaque PsoriasisCompletedNCT02660580Phase 3Results posted
• An Efficacy and Safety of Guselkumab in Participants With Palmoplantar PustulosisCompletedNCT02641730Phase 3Results posted
• A Study of the Efficacy and Safety of DFD-06 Cream in the Treatment of Moderate to Severe Plaque PsoriasisCompletedNCT02635204Phase 3Results posted
• A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque Psoriasis Naive to Systemic TreatmentCompletedNCT02634801Phase 3Results posted
• The Effect of Riboflavin on Moderate to Severe Plaque Type PsoriasisCompletedNCT02622386Phase 2Results posted
• Clinical Study to Evaluate the Efficacy and Safety of DSXS in Patients With Mild to Moderate Plaque PsoriasisCompletedNCT02618759Phase 3Results posted
• A Study to Determine the Efficacy of ZPL-3893787 in Subjects With Plaque PsoriasisCompletedNCT02618616Phase 2Results posted
• Study to Assess the Potential for Adrenal Suppression Following Treatment With DSXS in Patients With Plaque PsoriasisCompletedNCT02601469Phase 2Results posted
• Study to Evaluate Psoriasis Severity and Its Psychosocial Impact Using the Simplified Psoriasis Index (SPI), as Well as Long-term Safety, Tolerability and Efficacy of Secukinumab Administered Subcutaneously in Patients With Moderate to Severe PsoriasisCompletedNCT02595970Phase 3Results posted
• Immunologic Response to Secukinumab in Plaque PsoriasisCompletedNCT02592018Phase 4Results posted
• Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type PsoriasisCompletedNCT02581345Phase 3Results posted
• A Study of Safety, Tolerability and Pharmacokinetics of Apremilast (CC-10004) in Pediatric Subjects With Moderate to Severe Plaque PsoriasisCompletedNCT02576678Phase 2Results posted
• The Effect Of Smoking Status Of The Patient On The Success Of Etanercept Therapy In PsoriasisCompletedNCT02570750Results posted
• A Dose-Finding Study of GSK2894512 Cream in Subjects With Plaque PsoriasisCompletedNCT02564042Phase 2Results posted
• A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsoriasisCompletedNCT02561806Phase 3Results posted
• Evaluation of Cardiovascular Risk Markers in Psoriasis Patients Treated With SecukinumabCompletedNCT02559622Phase 3Results posted
• Psoriasis Microbiome and PhototherapyCompletedNCT02552316Not applicableResults posted
• Open-label Study of Subcutaneous Secukinumab to Evaluate Efficacy and Safety in Patients With Plaque Psoriasis Who Had Inadequate Response to Cyclosporine ACompletedNCT02547714Phase 4Results posted
• Safety and Effectiveness of Live Zoster Vaccine in Anti-Tumor Necrosis Factor (TNF) Users (VERVE Trial)CompletedNCT02538341Phase 2Results posted
• Study to Investigate Efficacy and Safety of Adalimumab in Japanese Subjects With Generalized Pustular Psoriasis (GPP)CompletedNCT02533375Phase 3Results posted
• DFD01 Spray HPA Axis Suppression Study in Adolescent Patients With Moderate to Severe Plaque PsoriasisTerminatedNCT02527421Phase 3Results posted
• A Psoriasis Plaque Test Trial With LEO 90100 Compared to Betesil® in Patients With Psoriasis VulgarisCompletedNCT02518048Phase 2Results posted
• Safety and Efficacy of IDP-122 in the Treatment of Participants With Plaque PsoriasisCompletedNCT02514577Phase 3Results posted
• A Study Comparing Different Dosing Regimens of Ixekizumab (LY2439821) in Participants With Moderate to Severe Plaque PsoriasisCompletedNCT02513550Phase 3Results posted
• Comparison of CHS-1420 Versus Humira in Subjects With Chronic Plaque PsoriasisCompletedNCT02489227Phase 3Results posted
• A Long Term Safety Extension Study (CHS-0214-05)CompletedNCT02486939Phase 3Results posted
• A Study To Evaluate The Efficacy Of Enbrel (REGISTERED) Etanercept Over A Period Of 12 Months In The Routine Treatment Of Patients With Rheumatoid Arthritis, Axial Spondyloarthritis, Psoriatic Arthritis, Or Plaque Psoriasis.CompletedNCT02486302Results posted
• Study of Secukinumab Compared to Fumaderm® in Adults With Moderate to Severe Psoriasis.CompletedNCT02474082Phase 3Results posted
• Secukinumab Dosage Optimisation in Partial Responders With Moderate to Severe Plaque-type PsoriasisCompletedNCT02474069Phase 3Results posted
• Pediatric Study in Children and Adolescents With Severe Plaque PsoriasisCompletedNCT02471144Phase 3Results posted
• Long-Term Safety of IDP-118 Lotion in the Treatment of Plaque PsoriasisCompletedNCT02462083Phase 3Results posted
• Safety and Efficacy of IDP-118 in the Treatment of Plaque PsoriasisCompletedNCT02462070Phase 3Results posted
• An ObserVatIonal STudy of the Effectiveness of AdaLimumab on Health and Disability Outcomes in New Zealand Patients With Immune-Mediated InflammaTorY Diseases (VITALITY)CompletedNCT02451839Results posted

← Psoriasis overview